Acumen Pharmaceuticals, Inc. (ABOS) vs KORU Medical Systems, Inc. (KRMD)
A side-by-side comparison of Acumen Pharmaceuticals, Inc. and KORU Medical Systems, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ABOS
Acumen Pharmaceuticals, Inc.
$2.03HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
KRMD
KORU Medical Systems, Inc.
$3.00HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — ABOS vs KRMD
growth of $100 · dividends reinvested · last 5yABOS -89.4% (-36.2%/yr)KRMD -35.0% (-8.3%/yr)KRMD compounded faster over this window
Log scale — wide-divergence pair
ABOS KRMD
ABOS vs KRMD: by the numbers
- •ABOS is the larger company ($147M vs $138M market cap).
- •Both run net losses; ABOS's is the smaller (0.00% vs -4.03% net margin).
Metrics side by side
Valuation
| Metric | ABOS | KRMD |
|---|---|---|
| P/S ratio | N/A | 3.05 |
| P/B ratio | 2.56 | 7.63 |
| FCF yield | N/A | 0.19% |
Profitability
| Metric | ABOS | KRMD |
|---|---|---|
| Gross margin | 0.00% | 61.99% |
| Operating margin | 0.00% | -3.66% |
| Net margin | 0.00% | -4.03% |
| ROE | -183.44% | -10.08% |
| ROIC | -118.67% | -7.95% |
Growth (annualized)
| Metric | ABOS | KRMD |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 16.42% |
| Total return CAGR (5Y) | -32.60% | 1.60% |
Frequently asked
- How have ABOS and KRMD total returns compared?
- Over the past 5 years, ABOS delivered -32.60% and KRMD delivered 1.60% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Acumen Pharmaceuticals ROEKORU Medical Systems ROEAcumen Pharmaceuticals operating marginKORU Medical Systems operating marginAcumen Pharmaceuticals revenue growthKORU Medical Systems revenue growthAcumen Pharmaceuticals free cash flowKORU Medical Systems free cash flow
Acumen Pharmaceuticals & KORU Medical Systems appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.